Can-Fite BioPharma (NYSE:CANF) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research note released on Tuesday. The brokerage issued a hold rating on the stock.

Separately, HC Wainwright reaffirmed a buy rating and issued a $18.00 price objective on shares of Can-Fite BioPharma in a research report on Thursday, May 9th.

Can-Fite BioPharma Price Performance

CANF opened at $2.56 on Tuesday. The company’s 50-day moving average is $2.41 and its 200 day moving average is $2.21. Can-Fite BioPharma has a fifty-two week low of $1.81 and a fifty-two week high of $4.48. The firm has a market capitalization of $9.06 million, a P/E ratio of -1.43 and a beta of 1.40.

Can-Fite BioPharma (NYSE:CANF) last released its quarterly earnings results on Thursday, March 28th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.20 million. Can-Fite BioPharma had a negative net margin of 1,027.46% and a negative return on equity of 113.75%. On average, equities research analysts expect that Can-Fite BioPharma will post -1.29 earnings per share for the current year.

Institutional Trading of Can-Fite BioPharma

An institutional investor recently bought a new position in Can-Fite BioPharma stock. Schechter Investment Advisors LLC purchased a new stake in Can-Fite BioPharma Ltd. (NYSE:CANF) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 20,077 shares of the company’s stock, valued at approximately $44,000. Schechter Investment Advisors LLC owned 0.57% of Can-Fite BioPharma as of its most recent SEC filing. Hedge funds and other institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.